famotidine (Pepcid, Apogastine)
Jump to navigation
Jump to search
Introduction
Tradename: Pepcid, Pepcid AC.
Indications
- dyspepsia
- prevention of peptic ulcer disease & erosive esophagitis in patients taking low-dose aspirin[4]
- prevention of GERD in patient with hiatal hernia
- stress ulceration & stress ulcer prophylaxis[5]
- investigational use for treatment of COVID-19[7]
Dosage
- 20 mg IV every 12 hours.
- 20-40 mg PO QHS.
- 10 mg with water 15-60 minutes before eating
- 60-240 mg PO QD used for treatment of non-hospitalized patients with COVID-19[6]
Tabs: 10, 20 & 400 mg
Suspension: 40 mg/5 mL
Dosage adjustment in renal failure
- reduce dose with eGFR < 50 mL/min[6]
- 36-48 hour dosing in patients with renal insufficiency[2].
Adverse effects
- adverse effects of 40 mg QHS similar to placebo[3]
- adverse effects which may be related to famotidine[3]
- headache 4.7%
- dizziness 1.3%
- constipation 1.2%
- diarrhea 1.7%
Toxicity:
- no data on deliberate overdose
- adults have been given up to 640 mg/day with no serious adverse effects[3]
Laboratory
More general terms
Component of
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ 2.0 2.1 Prescriber's Letter 8(5):26 2001
- ↑ 3.0 3.1 3.2 3.3 Physician's Desk Reference (PDR) 56th edition, Medical Economics, 2002
- ↑ 4.0 4.1 Taha AS Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet, Volume 374, Issue 9684, Pages 119-125, 11 July 2009 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19577798
- ↑ 5.0 5.1 Deprecated Reference
- ↑ 6.0 6.1 6.2 6.3 A Pocket Guide to the 2019 Beer's Criteria. American Geriatrics Society.
- ↑ 7.0 7.1 Cohen E, Nigam M Study shows Covid-19 patients who took heartburn drug were less likely to die, but researchers caution more research is needed. CNN Health. May 9, 2020. https://www.cnn.com/2020/05/09/health/famotidine-covid-19-correlation-study/index.html
Freedberg DE, Conigliaro J, Sobieszczyk ME et al Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Cohort Study. medRxiv. May 8, 2020 Not indexed in PubMed https://www.medrxiv.org/content/10.1101/2020.05.01.20086694v1
Freedberg DE, Conigliaro J, Wang TC et al Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology. 2020 May 22:S0016-5085(20)34706-5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32446698 Free PMC article
Walker M More Evidence Heartburn Drug May Help COVID-19 Patients - Another observational study adds fuel to the fire, but more research is needed. MedPage Today August 17, 2020 https://www.medpagetoday.com/infectiousdisease/covid19/88119
Mather JF, Seip RL, McKay RG et al Impact of famotidine use on clinical outcomes of hospitalized COVID-19 patients. Am J Gastroenterol; August 26, 2020. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32852338 https://journals.lww.com/ajg/Documents/AJG-20-2074_R1.pdf
Swift D Common Heartburn Drug for COVID-19 Symptoms? In case series, non-hospitalized patients felt better within 1-2 days of starting famotidine MedPage Today. June 4, 2020 https://www.medpagetoday.com/infectiousdisease/covid19/86893 - ↑ 8.0 8.1 Cohen E After hopeful early signs, study of popular heartburn drug shows mixed results against Covid-19. CNN Health. Feb 10, 2022 https://www.cnn.com/2022/02/10/health/covid-famotidine-study-results/index.html
- ↑ Department of Veterans Affairs, VA National Formulary